Full Press Release Details
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve tha